GMP compliance is deeply embedded into everyday operations for pharmaceutical manufacturers operating under an MIA. Quality systems, deviation management, validation, batch certification and GMP regulatory inspections are all familiar territory.
But what about their GDP responsibilities? Under the EU framework, manufacturers holding an MIA are authorised to distribute medicinal products by way of default and, because they operate to GMP they may unintentionally underestimate their GDP responsibilities.
This unintentional under prioritisation of GDP obligations can create significant compliance gaps, particularly with increasingly complex supply chains.
Distribution is often seen as an extension of logistics as opposed to a regulated distribution activity requiring dedicated oversight, thus creating a subtle but important risk. GDP responsibilities can become absorbed into existing GMP systems without sufficient evaluation of whether the systems actually meet GDP expectations.
Regulatory expectations are constantly increasing. Manufacturers are expected to demonstrate robust control across the entire supply chain, not just within the manufacturing site. Greater emphasis is now placed on:
– Supply Chain Governance
– Outsourced Logistics oversight
– Transportation risk management
– Data integrity in distribution systems
– Temperature controlled distribution
– Falsified medicines prevention
– End to end traceability
Strong GMP systems provide an excellent foundation for GDP compliance, but they are complementary, not interchangeable and not equivalent.
GMP focuses on ensuring products are consistently manufactured and controlled. GDP focuses on maintaining product quality and integrity throughout storage and distribution. Both are essential in protecting the end user.
A company can be extremely mature from a GMP perspective while still having relatively poor GDP governance. Warning signs to look out for include:
– GDP SOPs remain unchanged for years
– Infrequent or no specific GDP training
– Logistics vendors are rarely audited
– Transport risk assessments are static
– GDP topics rarely appear in management review meetings
– Inspection preparation focuses almost entirely on manufacturing operations
To reduce compliance risk manufacturers holding an MIA should periodically review whether they are meeting their GDP obligations. Steps to take include:
– Performing a dedicated GDP gap assessment
– Clarifying GDP responsibilities within the PQS
– Conducting management reviews focused on distribution risks
– Enhancing or introducing GDP specific training (many employees might have the training, but under the umbrella of GMP)
– Performing mock GDP inspections
– Assessing the need for a separate role profile with GDP responsibility
Holding an MIA may provide the legal framework for wholesale distribution activities, but it does not remove the need for a proactive GDP system that is fully implemented, maintained and continuously improved—not one that simply exists on paper.
Specialist pharmaceutical regulatory consulting services can help manufacturers identify GDP compliance gaps, strengthen supply-chain governance and prepare more effectively for regulatory inspections.
The most resilient organisations recognise that product quality does not end at batch release but continues all the way to the patient.
